Syndax Pharmaceuticals Inc License Agreements
15 Contracts & Agreements
- Amendment No. 1 to License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 9, 2019 (Filed With SEC on November 7, 2019)
- Amendment No. 1 to License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of January 25, 2019 (Filed With SEC on May 8, 2019)
- Amendment #4 to License, Development and Commercialization Agreement by and between the company and Kyowa Hakko Kirin Co., Ltd., dated May 29, 2018 (Filed With SEC on August 8, 2018)
- Amendment #3 to License, Development and Commercialization Agreement by and between the company and Kyowa Hakko Kirin Co., Ltd., dated March 27, 2018 (Filed With SEC on May 9, 2018)
- License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of October 13, 2017 (Filed With SEC on March 8, 2018)
- SIDE AGREEMENT to the License Agreement dated 1st July 2016 between UCB Biopharma Sprl and Syndax Pharmaceuticals, Inc. (License Agreement) (Filed With SEC on May 9, 2017)
- AMENDMENT #2 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on May 9, 2017)
- LICENSE AGREEMENT (Filed With SEC on October 7, 2016)
- AMENDMENT # 1 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on February 22, 2016)
- THIRD AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)
- SECOND AMENDMENT TO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)
- FIRST AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)
- THIRD AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)
- SECOND AMENDMENT TO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)
- FIRST AMENDMENTTO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)
